menu search

LOBEF / Lobe Sciences inks US$1.5M investment agreement to fund Australian clinical trials

Lobe Sciences inks US$1.5M investment agreement to fund Australian clinical trials
Lobe Sciences Ltd announced that it has entered into a term sheet with Cantheon Capital to raise up US$1.5 million, by means of a convertible note financing that would bear interest at 15% per annum with a term of 12 months, to conduct three clinical trials in Australia with partner iNGENu Pty Ltd.   The Canadian biopharmaceutical company said the convertible notes will help fund the design and conduct of clinical trials evaluating Lobe's proprietary psilocin analogues L-130 or L-131. Read More
Posted: Sep 1 2022, 10:26
Author Name: Proactive Investors
Views: 111845

LOBEF News  

Lobe Sciences appoints Mathew Lee as its next CFO

By Proactive Investors
September 18, 2023

Lobe Sciences appoints Mathew Lee as its next CFO

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) has announced Mathew Lee as its new Chief Financial Officer. Lee is the president of Manning Lee Management more_horizontal

Lobe Sciences announces amendment to Altemia acquisition agreement

By Proactive Investors
September 15, 2023

Lobe Sciences announces amendment to Altemia acquisition agreement

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) told investors that it signed an amendment to its April 18, 2023, share purchase agreement to acquire Altemi more_horizontal

Lobe Sciences provides further details regarding Altemia acquisition

By Proactive Investors
July 3, 2023

Lobe Sciences provides further details regarding Altemia acquisition

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) has provided further details regarding its acquisition of Altemia & Company LLC, first announced on April 1 more_horizontal

Lobe Sciences commences Phase 1 clinical study to evaluate L-130

By Proactive Investors
June 27, 2023

Lobe Sciences commences Phase 1 clinical study to evaluate L-130

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) said it has commenced a Phase 1 clinical study to evaluate L-130, their proprietary stabilized psilocin anal more_horizontal

Lobe Sciences appoints Baxter Phillips III as chief operating officer

By Proactive Investors
June 7, 2023

Lobe Sciences appoints Baxter Phillips III as chief operating officer

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) said it has appointed Baxter Phillips III to the newly created position of chief operating officer (COO) eff more_horizontal

Lobe Sciences names Pentec Health as exclusive US distributor of medical food Altemia for sickle cell disease

By Proactive Investors
May 17, 2023

Lobe Sciences names Pentec Health as exclusive US distributor of medical food Altemia for sickle cell disease

Lobe Sciences said it has entered into a commercial distribution agreement with Pentec Health for Altemia, a medical food with Lobe's proprietary form more_horizontal

Lobe Sciences stock flies after its new acquisition spells revenue

By Proactive Investors
April 18, 2023

Lobe Sciences stock flies after its new acquisition spells revenue

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) stock shot up Tuesday after the biopharma company said it had inked a share purchase agreement to acquire Al more_horizontal

Lobe Sciences boosts rare disease drug development portfolio with $3.8M acquisition

By Proactive Investors
April 18, 2023

Lobe Sciences boosts rare disease drug development portfolio with $3.8M acquisition

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) revealed that it has inked a share purchase agreement to acquire Altemia & Company LLC and all its assets, i more_horizontal


Search within

Pages Search Results: